IL10 and Insulin resistance: Results showed that IL10-MSCs could significantly counteract the HFD-induced obesity-related metabolic symptoms including body weight gain, hepatic and adipocyte lipids accumulation, glucose tolerance, insulin resistance, and serum lipid indicators, compared with unmodified MSCs.